## Wei Hua

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7251985/publications.pdf

Version: 2024-02-01

		567281	526287
89	971	15	27
papers	citations	h-index	g-index
92	92	92	967
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Permanent left bundle branch area pacing for atrioventricular block: Feasibility, safety, and acute effect. Heart Rhythm, 2019, 16, 1766-1773.	0.7	184
2	A Bioresorbable Dynamic Pressure Sensor for Cardiovascular Postoperative Care. Advanced Materials, 2021, 33, e2102302.	21.0	85
3	Left bundle branch area pacing delivery of cardiac resynchronization therapy and comparison with biventricular pacing. ESC Heart Failure, 2020, 7, 1711-1722.	3.1	79
4	Comparison of Left Bundle Branch and His Bundle Pacing in Bradycardia Patients. JACC: Clinical Electrophysiology, 2020, 6, 1291-1299.	3.2	64
5	Plasma NT pro-BNP, hs-CRP and big-ET levels at admission as prognostic markers of survival in hospitalized patients with dilated cardiomyopathy: a single-center cohort study. BMC Cardiovascular Disorders, 2014, 14, 67.	1.7	34
6	Comparison between his-bundle pacing and left bundle branch pacing in patients with atrioventricular block. Journal of Interventional Cardiac Electrophysiology, 2021, 62, 63-73.	1.3	33
7	Contrast-enhanced image-guided lead deployment for left bundle branch pacing. Heart Rhythm, 2021, 18, 1318-1325.	0.7	29
8	The Prevalence and Prognostic Effects of Subclinical Thyroid Dysfunction in Dilated Cardiomyopathy Patients: A Single-Center Cohort Study. Journal of Cardiac Failure, 2014, 20, 506-512.	1.7	26
9	The prognostic use of serum concentrations of cardiac troponin-I, CK-MB and myoglobin in patients with idiopathic dilated cardiomyopathy. Heart and Lung: Journal of Acute and Critical Care, 2014, 43, 219-224.	1.6	22
10	Comparison of the Prevalence, Clinical Features, and Long-term Outcomes of Midventricular Hypertrophy vs Apical Phenotype in Patients With Hypertrophic Cardiomyopathy. Canadian Journal of Cardiology, 2014, 30, 441-447.	1.7	21
11	Thyroidâ€stimulating hormone within the normal range and risk of major adverse cardiovascular events in nonischemic dilated cardiomyopathy patients with severe left ventricular dysfunction. Clinical Cardiology, 2019, 42, 120-128.	1.8	19
12	Permanent His Bundle Pacing Implantation Facilitated by Visualization of the Tricuspid Valve Annulus. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008370.	4.8	19
13	Visualization of tricuspid valve annulus for implantation of His bundle pacing in patients with symptomatic bradycardia. Journal of Cardiovascular Electrophysiology, 2019, 30, 2164-2169.	1.7	18
14	Plasma Metabolomic Profiles Differentiate Patients With Dilated Cardiomyopathy and Ischemic Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2020, 7, 597546.	2.4	18
15	Association between patient activity and long-term cardiac death in patients with implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators. European Journal of Preventive Cardiology, 2017, 24, 760-767.	1.8	17
16	Preventive Effectiveness of Implantable Cardioverter Defibrillator in Reducing Sudden Cardiac Death in the Chinese Population: A Multicenter Trial of ICD Therapy versus Nonâ€ICD Therapy. Journal of Cardiovascular Electrophysiology, 2012, 23, S5-9.	1.7	16
17	Longâ€term followâ€up of arrhythmogenic right ventricular cardiomyopathy patients with an implantable cardioverterâ€defibrillator for prevention of sudden cardiac death. Clinical Cardiology, 2017, 40, 216-221.	1.8	13
18	High sensitivity C-reactive protein and cardfiac resynchronization therapy in patients with advanced heart failure. Journal of Geriatric Cardiology, 2014, 11, 296-302.	0.2	11

#	Article	IF	CITATIONS
19	A feasible approach for His bundle pacing using aÂnovel mapping system in patients receiving pacemaker therapy. HeartRhythm Case Reports, 2019, 5, 433-435.	0.4	9
20	Comparison between His-bundle pacing guided by Ensite NavX system and conventional fluoroscopy. Journal of Interventional Cardiac Electrophysiology, 2020, 57, 107-114.	1.3	9
21	Dual antiplatelet therapy increases pocket hematoma complications in Chinese patients with pacemaker implantation. Journal of Geriatric Cardiology, 2015, 12, 383-7.	0.2	9
22	Conduction System Pacing for Post Transcatheter Aortic Valve Replacement Patients: Comparison With Right Ventricular Pacing. Frontiers in Cardiovascular Medicine, 2021, 8, 772548.	2.4	9
23	Association of baseline big endothelin-1 level with long-term prognosis among cardiac resynchronization therapy recipients. Clinical Biochemistry, 2018, 59, 25-30.	1.9	8
24	Left bundle branch pacing from distal Hisâ€bundle region by tricuspid valve annulus angiography. Journal of Cardiovascular Electrophysiology, 2019, 30, 2550-2553.	1.7	8
25	The clinical correlates and prognostic impact of QRS prolongation in patients with dilated cardiomyopathy: A single-center cohort study. International Journal of Cardiology, 2014, 172, e475-e477.	1.7	7
26	Acute and Chronic Changes and Predictive Value of Tpeak-Tend for Ventricular Arrhythmia Risk in Cardiac Resynchronization Therapy Patients. Chinese Medical Journal, 2016, 129, 2204-2211.	2.3	7
27	Biventricular pacemaker and defibrillator implantation in patients with chronic heart failure in China. ESC Heart Failure, 2021, 8, 546-554.	3.1	7
28	Comparison of electrical characteristics and pacing parameters of pacing different parts of the His-Purkinje system in bradycardia patients. Journal of Interventional Cardiac Electrophysiology, 2022, 63, 175-183.	1.3	7
29	Novel Wide-Band Dielectric Imaging System Guided Lead Deployment for His Bundle Pacing: A Feasibility Study. Frontiers in Cardiovascular Medicine, 2021, 8, 712051.	2.4	7
30	Electrical characteristics of pacing different portions of the His bundle in bradycardia patients. Europace, 2020, 22, ii27-ii35.	1.7	7
31	Nomogram predicting death and heart transplantation before appropriate ICD shock in dilated cardiomyopathy. ESC Heart Failure, 2022, , .	3.1	7
32	The role of variability in night-time mean heart rate on the prediction of ventricular arrhythmias and all-cause mortality in implantable cardioverter defibrillator patients. Europace, 2015, 17, ii76-ii82.	1.7	6
33	Effects of ventricular conduction block patterns on mortality in hospitalized patients with dilated cardiomyopathy: a single-center cohort study. BMC Cardiovascular Disorders, 2016, 16, 136.	1.7	6
34	Cardiac resynchronization therapy using left ventricular septal pacing: An alternative to biventricular pacing?. HeartRhythm Case Reports, 2019, 5, 426-429.	0.4	6
35	Predictive value of rapid-rate non-sustained ventricular tachycardia in the occurrence of appropriate implantable cardioverter-defibrillator therapy. Journal of Interventional Cardiac Electrophysiology, 2020, 57, 473-480.	1.3	6
36	Overweight and obesity as protective factors against mortality in nonischemic cardiomyopathy patients with an implantable cardioverter defibrillator. Clinical Cardiology, 2020, 43, 1435-1442.	1.8	6

#	Article	IF	CITATIONS
37	Comprehensive plasma metabolites profiling reveals phosphatidylcholine species as potential predictors for cardiac resynchronization therapy response. ESC Heart Failure, 2021, 8, 280-290.	3.1	6
38	Left ventricular involvement assessed by LGE-CMR in predicting the risk of adverse outcomes of arrhythmogenic cardiomyopathy with ICDs. International Journal of Cardiology, 2021, 337, 79-85.	1.7	6
39	High incidence of ventricular arrhythmias in patients with left ventricular enlargement and moderate left ventricular dysfunction. Clinical Cardiology, 2016, 39, 703-708.	1.8	5
40	Electrical Storm in ICD Recipients with Arrhythmogenic Right Ventricular Cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 683-692.	1.2	5
41	Prognostic significance of frequent premature ventricular complex early after implantation among patients with implantable cardioverter defibrillator. Journal of Electrocardiology, 2018, 51, 898-905.	0.9	5
42	Left bundle branch pacing, the only feasible physiological pacing modality for a patient with complete atrioventricular septal defect after surgical correction. Journal of Cardiovascular Electrophysiology, 2019, 30, 3002-3005.	1.7	4
43	Predictive value of Tpeak-Tend interval for ventricular arrhythmia and mortality in heart failure patients with an implantable cardioverter-defibrillator. Medicine (United States), 2019, 98, e18080.	1.0	4
44	Prognostic impact of right bundle branch block in hospitalized patients with idiopathic dilated cardiomyopathy: a single-center cohort study. Journal of International Medical Research, 2020, 48, 030006051880147.	1.0	4
45	3.0 T magnetic resonance imaging scanning on different body regions in patients with pacemakers. Journal of Interventional Cardiac Electrophysiology, 2021, 61, 545-550.	1.3	4
46	Prognostic effects of longitudinal changes in left ventricular ejection fraction with cardiac resynchronization therapy. ESC Heart Failure, 2021, 8, 368-379.	3.1	4
47	Left ventricularâ€only fusion pacing versus cardiac resynchronization therapy in heart failure patients: A randomized controlled trial. Clinical Cardiology, 2021, 44, 1225-1232.	1.8	4
48	Characteristics and Long-Term Ablation Outcomes of Supraventricular Arrhythmias in Hypertrophic Cardiomyopathy: A 10-Year, Single-Center Experience. Frontiers in Cardiovascular Medicine, 2021, 8, 766571.	2.4	4
49	A Comparison of the Electrophysiological and Anatomic Characteristics of Pacing Different Branches of the Left Bundle Conduction System. Frontiers in Cardiovascular Medicine, 2021, 8, 781845.	2.4	4
50	Validation of an Arrhythmogenic Right Ventricular Cardiomyopathy Risk-Prediction Model in a Chinese Cohort. Journal of Clinical Medicine, 2022, 11, 1973.	2.4	4
51	Optimal Lesion Size Index for Pulmonary Vein Isolation in High-Power Radiofrequency Catheter Ablation of Atrial Fibrillation. Frontiers in Cardiovascular Medicine, 2022, 9, 869254.	2.4	4
52	Cardiac Troponin T (TNNT2) Mutations in Chinese Dilated Cardiomyopathy Patients. BioMed Research International, 2014, 2014, 1-7.	1.9	3
53	Cardiac resynchronization therapy reduces T-wave alternans in patients with heart failure. Europace, 2015, 17, 281-288.	1.7	3
54	Sacubitril/Valsartan in the Management of Heart Failure Patients with Cardiac Implantable Electronic Devices. American Journal of Cardiovascular Drugs, 2020, 21, 383-393.	2.2	3

#	Article	IF	CITATIONS
55	Association of the Obesity Paradox With Objective Physical Activity in Patients at High Risk of Sudden Cardiac Death. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4801-e4810.	3.6	3
56	A novel risk model for mortality and hospitalization following cardiac resynchronization therapy in patients with non-ischemic cardiomyopathy: the alpha-score. BMC Cardiovascular Disorders, 2020, 20, 205.	1.7	3
57	The Clinical Prognosis of Presence and Location of Late Gadolinium Enhancement by Cardiac Magnetic Resonance Imaging in Patients with Hypertrophic Cardiomyopathy: a Single-Center Cohort Study. Journal of Cardiovascular Translational Research, 2021, 14, 1001-1016.	2.4	3
58	The gender difference of utilization of cardiac implantable electronic device in China: data from Arrhythmia Interventional Therapy Data Registry. Journal of Geriatric Cardiology, 2018, 15, 310-314.	0.2	3
59	N-Terminal Pro-B-Type Natriuretic Peptide in Risk Stratification of Heart Failure Patients With Implantable Cardioverter-Defibrillator. Frontiers in Cardiovascular Medicine, 2022, 9, 823076.	2.4	3
60	Prediction of ventricular arrhythmia events in ischemic heart disease patients with implantable cardioverter-defibrillators. Journal of Materials Science: Materials in Medicine, 2015, 26, 240.	3.6	2
61	Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients. BMC Cardiovascular Disorders, 2019, 19, 230.	1.7	2
62	Electrocardiographic characteristics of distal His bundle pacing in a patient with left bundle branch block. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1594-1596.	1.2	2
63	Predictive value of gamma-glutamyltransferase for ventricular arrhythmias and cardiovascular mortality in implantable cardioverter-defibrillator patients. BMC Cardiovascular Disorders, 2019, 19, 129.	1.7	2
64	A Predictive Model for Super-Response to Cardiac Resynchronization Therapy: The QQ-LAE Score. Cardiology Research and Practice, 2020, 2020, 1-8.	1.1	2
65	Sex Differences in Physical Activity and Its Association With Cardiac Death and All-Cause Mortality in Patients With Implantable Cardioverter-Defibrillators. Frontiers in Cardiovascular Medicine, 2020, 7, 588622.	2.4	2
66	Association between cardiac autonomic function and physical activity in patients at high risk of sudden cardiac death: a cohort study. International Journal of Behavioral Nutrition and Physical Activity, 2021, 18, 128.	4.6	2
67	Association of Night-Time Heart Rate With Ventricular Tachyarrhythmias, Appropriate and Inappropriate Implantable Cardioverter-Defibrillator Shocks. Frontiers in Cardiovascular Medicine, 2021, 8, 739889.	2.4	2
68	Heart rate-adjusted PR as a prognostic marker of long-term ventricular arrhythmias and cardiac death in ICD/CRT-D recipients. Journal of Geriatric Cardiology, 2019, 16, 259-264.	0.2	2
69	Short-Term Availability of Viable Left Ventricular Pacing Sites with Quartetâ,, Quadripolar Leads. Medical Science Monitor, 2017, 23, 767-773.	1.1	2
70	Significant mitral regurgitation as a predictor of long-term prognosis in patients receiving cardiac resynchronisation therapy. Kardiologia Polska, 2018, 76, 987-992.	0.6	2
71	Predictors of non-response to cardiac resynchronization therapy implantation in patients with class I indications: the markedly dilated left ventricular end-diastolic dimension and the presence of fragmented QRS. Journal of Geriatric Cardiology, 2019, 16, 514-521.	0.2	2
72	The effects of smoking and drinking on all-cause mortality in patients with dilated cardiomyopathy: a single-center cohort study. European Journal of Medical Research, 2015, 20, 78.	2.2	1

#	Article	IF	Citations
73	Plasticity of left ventricular function with cardiac resynchronization therapy. Journal of Interventional Cardiac Electrophysiology, 2020, 57, 289-294.	1.3	1
74	Multipolar mapping for catheter ablation of premature ventricular complexes originating from papillary muscles in the structurally normal heart: a case series. BMC Cardiovascular Disorders, 2020, 20, 464.	1.7	1
75	Dose-response association of implantable device-measured physical activity with long-term cardiac death and all-cause mortality in patients at high risk of sudden cardiac death: a cohort study. International Journal of Behavioral Nutrition and Physical Activity, 2020, 17, 119.	4.6	1
76	Echocardiographic Predictors of All-Cause Mortality in Patients with Hypertrophic Cardiomyopathy following Pacemaker Implantation. Cardiology Research and Practice, 2020, 2020, 1-7.	1.1	1
77	Global and regional cardiac dysfunction quantified by 18F-FDG PET scans can predict ventricular arrhythmia in patients with implantable cardioverter defibrillator. Journal of Nuclear Cardiology, 2021, 28, 464-477.	2.1	1
78	The implantation technique in His-bundle pacing: evolution and perspectives. Europace, 2020, 22, ii3-ii9.	1.7	1
79	Association Between Subcutaneous Implantable Cardioverter Defibrillator Preimplantation Screening and the Response to Cardiac Resynchronization Therapy. Korean Circulation Journal, 2020, 50, 1062.	1.9	1
80	Plasma big endothelin-1 is an effective predictor for ventricular arrythmias and end-stage events in primary prevention implantable cardioverter- defibrillator indication patients. Journal of Geriatric Cardiology, 2020, 17, 427-433.	0.2	1
81	Implantable device measured objective daily physical activity as a predictor of long-term all-cause mortality and cardiac death in patients with age > 75 years and high risk of sudden cardiac death: cohort study. BMC Geriatrics, 2022, 22, 130.	<b>2.</b> 7	1
82	Mitral Regurgitation and Body Mass Index Increase the Predictability of Perioperative Bleeding in Anticoagulated Patients With Nonvalvular Atrial Fibrillation. Frontiers in Cardiovascular Medicine, 2022, 9, 846590.	2.4	1
83	Absence of Obesity Paradox in All-Cause Mortality Among Chinese Patients With an Implantable Cardioverter Defibrillator: A Multicenter Cohort Study. Frontiers in Cardiovascular Medicine, 2021, 8, 730368.	2.4	1
84	Association of time-varying changes in physical activity with cardiac death and all-cause mortality after ICD or CRT-D implantation Journal of Geriatric Cardiology, 2022, 19, 177-188.	0.2	1
85	Prediction Efficiency of MADIT-ICD Benefit Score for Outcome in Asian Patients with Implantable Cardioverter-Defibrillator. International Journal of General Medicine, 2022, Volume 15, 4409-4416.	1.8	1
86	Non-linear Association Between Body Mass Index and Ventricular Tachycardia/Ventricular Fibrillation in Patients With an Implantable Cardioverter-Defibrillator or Cardiac Resynchronization Therapy Defibrillator: A Multicenter Cohort Study. Frontiers in Cardiovascular Medicine, 2020, 7, 610629.	2.4	0
87	Validation of Three European Risk Scores to Predict Long-Term Outcomes for Patients Receiving Cardiac Resynchronization Therapy in an Asian Population. Journal of Cardiovascular Translational Research, 2020, 14, 754-760.	2.4	O
88	Association Between Changes in Physical Activity and New-Onset Atrial Fibrillation After ICD/CRT-D Implantation. Frontiers in Cardiovascular Medicine, 2021, 8, 693458.	2.4	0
89	Comorbid Hypertension Reduces the Risk of Ventricular Arrhythmia in Chronic Heart Failure Patients with Implantable Cardioverter-Defibrillators. Journal of Clinical Medicine, 2022, 11, 2816.	2.4	O